Filing Details

DarioHealth Corp. (“Issuer”)

142 W. 57th St., 8th Floor

New York, New York 10019

The names of the persons filing this statement on Schedule 13G are (collectively, the “Reporting Persons”):

•	Collaborative Holdings Master Fund LP, a Cayman Islands exempted limited partnership (the “Master Fund”);

•	Collaborative Holdings Fund GP LLC, a Delaware limited liability company (“Collaborative Fund GP”)

•	Collaborative Holdings Management LP, a Delaware limited partnership (“Collaborative Management”);

•	Collaborative Holdings GP LLC, a Delaware limited liability company (“IM GP”); and

•	Sheetal Sharma, a United States citizen (“Mr. Sharma”);

Collaborative Fund GP acts as the general partner of, and Collaborative Management acts as the investment manager of, the Master Fund.  IM GP acts as the general partner of Collaborative Management.  Mr. Sharma is the Managing Member of each of Collaborative Fund GP and IM GP.

By virtue of these relationships, each of Collaborative Fund GP, Collaborative Management, IM GP, and Mr. Sharma may be deemed to have voting and dispositive power with respect to the shares of Common Stock (as defined below) owned by the Master Fund.

The principal business address of each of Collaborative Fund GP, Collaborative Management, IM GP, and Mr. Sharma is 347 Bowery, 2^nd Floor, New York, New York 10003.

The principal business address of the Master Fund is c/o Walkers Corporate Limited, Cayman Corporate Centre, 27 Hospital Road, Grand Cayman, Cayman Islands, KY1-9008.

Mr. Sharma is a citizen of the United States.

The Master Fund is an exempted limited partnership formed under the laws of the Cayman Islands.

Collaborative Fund GP is a limited liability company formed under the laws of the State of Delaware.

Collaborative Management is a limited partnership formed under the laws of the State of Delaware.

IM GP is a limited liability company formed under the laws of the State of Delaware.

Common stock, par value $0.0001 per share (“Common Stock”)

23725P209

Item 4.   Ownership.

As of the close of business on July 7, 2021,

(i)	The Master Fund owned 829,304 shares of Common Stock;

(ii)	Collaborative Fund GP, as the general partner of the Master Fund, may be deemed to beneficially own the 829,304 shares of Common Stock owned by the Master Fund;

(iii)

Collaborative Management, as the investment manager of the Master Fund, may be deemed to beneficially own the 829,304 shares of Common Stock owned by the Master Fund;

(iv)	IM GP, as the general partner of Collaborative Management, may be deemed to beneficially own the 829,304 shares of Common Stock owned by the Master Fund and Collaborative Management.

(v)	Mr. Sharma, as the Managing Member of each of Collaborative Fund GP and IM GP, may be deemed to beneficially own the 829,304 shares of Common Stock owned by the Master Fund and Collaborative Fund GP and Collaborative Management.

The percentage of Common Stock reported owned by each person named herein is based upon 16,441,716 shares of Common Stock outstanding as of June 7, 2021, as reported in the Issuer’s 8-K filed with the Securities and Exchange Commission on June 8, 2021. As of the close of business on July 7, 2021, each of the Reporting Persons may be deemed to beneficially own 5.04% of the outstanding shares of Common Stock.

(i) Sole power to vote or to direct the vote:

See Cover Pages Items 5-8.

(ii) Shared power to vote or to direct the vote:

See Cover Pages Items 5-8.

(iii) Sole power to dispose or to direct the disposition:

See Cover Pages Items 5-8.

(iv) Shared power to dispose or to direct the disposition:

See Cover Pages Items 5-8.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

Not applicable.

Not applicable.

Not applicable.

Not applicable.

By signing below each of the undersigned certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

*The Reporting Persons disclaim beneficial ownership in the shares of Common Stock reported herein except to the extent of their pecuniary interest therein. The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock, par value $0.0001 per share, of DarioHealth Corp. dated  July [ ], 2021 and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.